# China NMPA Drug Inspection - Harbin Runhe Traditional Chinese Medicine Processing Plant - earth dragon

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/harbin-runhe-traditional-chinese-medicine-processing-plant/46aa1240-443d-496d-9caf-56c234dda58d/
Source feed: China

> China NMPA drug inspection for Harbin Runhe Traditional Chinese Medicine Processing Plant published March 03, 2020. Drug: earth dragon. On March 3, 2020, the Jilin Provincial Drug Administration published the first issue of its 2020 Drug Quality Bulletin, 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Jilin Province Drug Quality Bulletin (Issue 1, 2020)
- Company Name: Harbin Runhe Traditional Chinese Medicine Processing Plant
- Publication Date: 2020-03-03
- Drug Name: earth dragon
- Inspection Finding: Characteristics (properties) are unqualified
- Action Taken: Drug regulatory authorities have required relevant entities to take risk control measures and investigate and punish substandard products in accordance with relevant laws and regulations.
- Summary: On March 3, 2020, the Jilin Provincial Drug Administration published the first issue of its 2020 Drug Quality Bulletin, detailing the results of a province-wide sampling inspection aimed at ensuring public safety. The inspection identified seventeen batches of substandard products across several manufacturers and medical facilities, including Anhui Huadingtang Traditional Chinese Medicine Pieces, Songyuan City Traditional Chinese Medicine Hospital, Jilin Hengjin Pharmaceutical, and Changchun Dirui Pharmaceutical. Main violations discovered during the testing included excessive organochlorine pesticide residues in Ginseng, high microbial levels and inconsistent fill weights in various hospital-prepared capsules, and the presence of visible foreign matter in eye drops. Additionally, several traditional medicine pieces failed potency tests for active ingredients or contained excessive ash. The inspections were conducted under the regulatory framework of the Chinese Pharmacopoeia (2015 Edition), National Medical Products Administration (NMPA) standards, and Jilin Provincial medical preparation guidelines. In response to these findings, the provincial authority has mandated that all relevant units implement immediate risk control measures and handle the non-compliant products according to established laws and regulations to prevent public harm.

Company: https://www.globalkeysolutions.net/companies/harbin-runhe-traditional-chinese-medicine-processing-plant/e04c6e2e-d4c8-49b1-a4f7-7cfe265123dc/